High Conviction, Patient 61, and the Future of CAR T-Cell Therapy: with JR, CEO of BioOra

In this episode of Snowball, host Tom Morton sits down with John Robson (JR), CEO of BioOra, to explore the intersection of high-conviction capital and ground-breaking science.In this episode, we discuss:The "Dark Arts" vs. Hard Science: Why London’s macro-finance floors are a blend of math and "witchcraft," and how a background in biochemistry prepares you for high-stakes capital allocation.High Conviction vs. "Spray and Pray": JR explains the "Be a bull, be a bear, but never be a pig" philosophy and why the most successful investors double down on their winners.The "Lobster Pot" of NZ Capital: Why local venture funds often fear deep-tech and how the "Series A gap" is forcing Kiwi founders to look toward the US for valuation and validation.Infrastructure as a Business Model: Why BioOra isn't just a "drug discovery" play, but a manufacturing foundry designed to build sovereign healthcare capability for the South Pacific.The Economics of the "Safety Switch": How a technical breakthrough in CAR T-cell therapy removes the need for ICU care, turning a $1.5 million treatment into an economically viable solution for New Zealand.The Mission of "Patient 61": The human side of the capital pathway, ensuring that the "Snowball" doesn't stop once the clinical trials end.About John Robson (JR) & BioOra:John Robson, widely known as JR, is a seasoned capital allocator and CEO with over 35 years of experience spanning London’s high-finance floors and New Zealand’s tech sector. From managing billions at Mercury Asset Management and Merrill Lynch to scaling Provoke Solutions from 30 to 160 people, JR brings a rare "allocator’s lens" to the world of deep-tech innovation.BioOra is a Christchurch-based biotechnology company born out of a collaboration with the Malaghan Institute. Backed by the Bridgewest Group, the firm is dedicated to democratising CAR T-cell therapy. By building the infrastructure to manufacture personalised cancer treatments locally, BioOra is securing New Zealand’s sovereign capability in the next revolution of immunotherapy, ensuring that life-saving treatments are both safe and accessible.About Snowball:Snowball is New Zealand’s leading private equity and investment platform, dedicated to simplifying access to growth and alternative assets. Since 2014, the platform has helped over 100 high-growth Kiwi companies raise more than $200 million in capital, serving a community of over 55,000 investors.Beyond direct equity, Snowball provides self-directed access to a curated range of global alternative strategies, including private credit, infrastructure, private equity, and long-short funds, often with significantly lower entry points than traditional institutional channels.Learn more and explore the investible universe at www.snowballeffect.co.nz